In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice: M. Chu, et al.; Immunobiology 222, 483 (2017)
The effect of interleukin 38 on angiogenesis in a model of oxygen-induced retinopathy: J. Zhang, et al.; Sci. Rep. 7, 2756 (2017)
The enigmatic role of IL-38 in inflammatory diseases: T. Garraud, et al.; Cytokine Growth Factor Rev. 39, 26 (2018)
Interleukin 38 protects against lethal sepsis: F. Xu, et al.; J. Infect. Dis. 218, 1175 (2018)
The Effect of Interleukin 38 on Inflammation-induced Corneal Neovascularization: J. Zhu, et al.; Curr. Mol. Med. 19, 589 (2018)
Interleukin‐38 alleviates cardiac remodelling after myocardial infarction: Y. Wei, et al.; J. Cell. Mol. Med. 24, 371 (2020)
IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis: W.D. Xu, et al.; J. Cell Mol. Med. 24,12379 (2020)
IL-38 Alleviates Inflammation in Sepsis in Mice by Inhibiting Macrophage Apoptosis and Activation of the NLRP3 Inflammasome: Y. Ge, et al.; Mediat. Inflamm. 6370911 (2021)
Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity: H. Li, et al.; Invest. Ophthalmol. Vis. Sci. 62, (2021)
Multifaceted roles of IL-38 in inflammation and cancer: A. Diaz-Barreiro, et al.; Cytokine 151, 155808 (2022)
IL-38, a potential therapeutic agent for lupus, inhibits lupus progression: WD. Xu, et al.; Inflamm. Res. 71, 963 (2022)
Regulatory effect of IL-38 on NF-κB pathway in systemic lupus erythematosus: J. Zhang, et al.; Immunobiol. ahead of print (2022)